Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period

Autor: Kress, Hans Georg, Orońska, Anna, Kaczmarek, Zbigniew, Kaasa, Stein, Colberg, Torben, Nolte, Thomas
Zdroj: In Clinical Therapeutics 2009 31(6):1177-1191
Databáze: ScienceDirect
Externí odkaz: